ReviewWorld journal of gastroenterology2022
Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma.
Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of machine perfusion in preventing recurrence after liver transplant for hepatocellular carcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Refining the role of liver transplantation as a curative treatment for hepatocellular carcinoma.International journal of clinical oncology · 2026Review
- Systemic Treatment for Hepatocellular Carcinoma Recurrence After Liver Transplantation.Current oncology (Toronto, Ont.) · 2026Review
- Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions.Journal of clinical medicine · 2025Review
- Augmenting conventional criteria: a CT-based deep learning radiomics nomogram for early recurrence risk stratification in hepatocellular carcinoma after liver transplantation.Insights into imaging · 2025Article
- Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma.Gastroenterology & hepatology · 2025Article
- Hepatocellular Carcinoma and the Role of Liver Transplantation: An Update and Review.Journal of clinical and translational hepatology · 2025Review
- Evolutionary dynamics of recurrent hepatocellular carcinoma under divergent immune selection pressures.Frontiers in oncology · 2025Article
- Prediction of Non-Transplantable Recurrence After Liver Resection for Solitary Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Article
- The Role of Liver Transplantation in the Treatment of Liver Metastases from Neuroendocrine Tumors.Current treatment options in oncology · 2023Review
- Recent advances in recurrent hepatocellular carcinoma therapy.World journal of hepatology · 2023Review
- 2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite stringent selection criteria, hepatocellular carcinoma recurrence after liver transplantation (LT) still occurs in up to 20% of cases, mostly within the first 2-3 years. No adjuvant treatments to prevent such an occurrence have been developed so far. However, a balanced use of immunosuppression with minimal dose of calcineurin inhibitors and possible addition of mammalian target of rapamycin inhibitors is strongly advisable. Moreover, several pre- and post-transplant predictors of recurrence have been identified and may help determine the frequency and duration of post-transplant follow-up. When recurrence occurs, the outcomes are poor with a median survival of 12 mo according to most retrospective studies. The factor that most impacts survival after recurrence is timing (within 1-2 years from LT according to different authors). Several therapeutic options may be chosen in case of recurrence, according to timing and disease presentation. Surgical treatment seems to provide a survival benefit, especially in case of late recurrence, while the benefit of locoregional treatments has been suggested only in small retrospective studies. When systemic treatment is indicated, sorafenib has been proved safe and effective, while only few data are available for lenvatinib and regorafenib in second line. The use of immune checkpoint inhibitors is controversial in this setting, given the safety warnings for the risk of acute rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.